VYNE Therapeutics Inc. · NASDAQ:VYNE
VYNE Therapeutics — Technical Presentation (July 2025)
35 slides from VYNE Therapeutics's technical presentation, July 2025
Slide 1: VYN202 Phase 1b Moderate-to-Severe PsO
VYN202 Phase 1b Moderate-to-Severe PsO July 2025 1
Slide 2: Forward Looking Statements and Important Notes
Forward Looking Statements and Important Notes This presentation by VYNE Therapeutics Inc. (“VYNE”) includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 including, but not limited to, statements regarding VYNE’s development plans and timeline
Slide 3: VYN202: A Novel BD2-Selective BET Inhibitor for Immune-Mediated Diseases
VYN202: A Novel BD2-Selective BET Inhibitor for Immune-Mediated Diseases • VYN202 is an innovative, oral BD2-selective BET inhibitor • VYN202 is believed to be the most potent and BD2-selective BET Inhibitor in clinical development1 which is designed to improve efficacy and tolerability • Program su
Slide 4: VYN202 Phase 1b Study Design in Moderate-to-Severe Plaque Psoriasis
VYN202 Phase 1b Study Design in Moderate-to-Severe Plaque Psoriasis N = up to 80 subjects with moderate-to-severe plaque psoriasis Screening period Placebo-controlled treatment period Safety follow-up (30 days) (12 weeks) (4 weeks) Key Inclusion Criteria • 18-75 y VYN202 1 mg QD (N=~20) • BMI 18-40
Slide 5: VYN202 Phase 1b Study: Patients Enrolled
VYN202 Phase 1b Study: 7 Patients Enrolled Demographic and Patient Characteristics Duration of treatment Subject Dose Parameter Value BL Week 1 Week 2 Week 4 Week 6 Week 8 Week 12 Week 16 ID (mg) Mean Age, yr (min-max) 47.1 (30-59) A Pbo 24 Days Sex, M/F 5/2 B 0.25 64 Days Race White (7) C 0.50 14 D
Slide 6: Subject A, Male (Placebo) - Efficacy
Subject A, Male (Placebo) - Efficacy Visit Baseline Week 1 Week 2 Week 4 Week 6 Week 8 Week 12 Dosing Duration 10MAR 03APR (24 days) PASI Score 26.7 26.7 26.7 26.7 26.7 - - PSSI Score 24 24 24 24 24 - - sPGA Score 3 3 3 3 3 - - BSA 34 34 34 34 34 - - Itch NRS 8 10 9 9 9 - - Joint Pain NRS 8 8 8 9 9
Slide 7: Subject A, Male (Placebo) – Serum Biomarkers
Subject A, Male (Placebo) – Serum IL19, IL17A, IL17F & IL22 Biomarkers IL19, pg/ml IL17A, pg/ml 1000 35 30 800 25 IL17A, pg/ml IL19, pg/ml 600 20 400 15 10 200 5 0 0 0 2 4 6 8 10 12 14 16 0 2 4 6 8 10 12 14 16 Study Week Study Week IL17F, pg/ml IL22, pg/ml 30 20 25 15 IL17F, pg/ml 20 IL22, pg/ml 15
Slide 8: Subject A, Male (Placebo) – Safety & Key Labs
Subject A, Male (Placebo) – Safety & Key Labs 500 400 0.00mg Platelet Counts 300 LLN ULN 200 100 0 -4 -2 0 2 4 6 8 10 12 14 16 10.0 8.0 0.00mg Neutrophil Counts 6.0 LLN ULN 4.0 2.0 0.0 -4 -2 0 2 4 6 8 10 12 14 16 3.5 3.0 Lymphocyte 2.5 0.00mg Counts 2.0 LLN 1.5 ULN 1.0 0.5 0.0 -4 -2 0 2 4 6 8 10 12
Slide 9: Subject B, Female (0.25mg) - Efficacy
Subject B, Female (0.25mg) - Efficacy Visit Baseline Week 1 Week 2 Week 4 Week 6 Week 8 Week 12 Week 16 Dosing Duration 26MARFEB 24APR (64 days) PASI Score 13.9 15.5 15.1 10.3 6.9 5.4 5.4 5.4 PSSI Score 14 14 14 8 4 4 4 4 sPGA Score 3 3 3 2 1 1 1 1 BSA 14 14 14 11 11 10 10 10 Itch NRS 9 7 7 6 5 7 4
Slide 10: Subject B, Female (0.25mg) - Serum Biomarkers
Subject B, Female (0.25mg) - Serum IL19, IL17A, IL17F & IL22 Biomarkers IL19, pg/ml IL17A, pg/ml 80 16 70 14 60 12 -49% IL17A, pg/ml IL19, pg/ml 50 10 40 8 -66% 30 6 20 4 10 2 0 0 0 2 4 6 8 10 12 14 16 0 2 4 6 8 10 12 14 16 Study Week Study Week IL17F, pg/ml IL22, pg/ml 10.0 14 12 8.0 -39% 10 IL22,
Slide 11: Subject B, Female (0.25mg) – Safety & Key Labs
Subject B, Female (0.25mg) – Safety & Key Labs 500 400 (x103/mm3) 0.25mg Platelet Counts 300 LLN 200 ULN 100 Nadir at 0 Week 6 -4 -2 0 2 4 6 8 10 12 14 16 10.0 8.0 (x103/mm3) Neutrophil 0.25mg Counts 6.0 LLN 4.0 ULN 2.0 0.0 -4 -2 0 2 4 6 8 10 12 14 16 3.5 Lymphocyte 3.0 (x103/mm3) Counts 2.5 0.25mg
Slide 12: Subject C, Male (0.5mg) - Efficacy
Subject C, Male (0.5mg) - Efficacy Visit Baseline Week 1 Week 2 Week 4 Week 6 Week 8 Week 12 Dosing Duration 19MAR 02APR (14 days) PASI Score 23 14.1 13.5 22 19.6 21.7 20.8 PSSI Score 12 3 3 10 10 10 10 sPGA Score 3 2 2 3 4 4 4 BSA 37 27 26 29 28.5 34 35 Itch NRS 6 3 3 3 5 8 8 Joint Pain NRS 7 5 3 3
Slide 13: Subject C, Male (0.5mg) - Serum Biomarkers
Subject C, Male (0.5mg) - Serum IL19, IL17A, IL17F & IL22 Biomarkers IL19, pg/ml IL17A, pg/ml 350 3 300 2.5 250 IL17A, pg/ml IL19, pg/ml 2 200 1.5 150 100 -27% 1 -30% 50 0.5 0 0 0 2 4 6 8 10 12 14 16 0 2 4 6 8 10 12 14 16 Study Week Study Week IL17F, pg/ml IL22, pg/ml 12 16 14 10 12 IL17F, pg/ml IL2
Slide 14: Subject C, Male (0.5mg) – Safety & Key Labs
Subject C, Male (0.5mg) – Safety & Key Labs 500 400 (x103/mm3) Platelet Counts 300 0.50mg LLN 200 ULN 100 0 -4 -2 0 2 4 6 8 10 12 14 16 10.0 8.0 (x103/mm3) Neutrophil Counts 6.0 0.50mg LLN 4.0 ULN 2.0 0.0 -4 -2 0 2 4 6 8 10 12 14 16 3.5 Lymphocyte (x103/mm3) 3.0 Counts 2.5 2.0 0.50mg 1.5 LLN 1.0 ULN
Slide 15: Subject D, Male (0.5mg) - Efficacy
Subject D, Male (0.5mg) - Efficacy Visit Baseline Week 1 SFU Dosing Duration 26MAR 02APR (7 days) 30APR PASI Score 20.1 20.1 14.8 PSSI Score 3 - - sPGA Score 3 3 3 BSA 31 31 32 Itch NRS 9 10 10 Joint Pain NRS N/A N/A N/A (0.5mg) (0.5mg) Comments: 0% 4 • Subject on active drug for 7 days -10% • Safet
Slide 16: Subject D, Male (0.5mg) – Safety & Key Labs
Subject D, Male (0.5mg) – Safety & Key Labs 500 400 (x103/mm3) 0.50mg Platelet Counts 300 LLN 200 ULN 100 0 -4 -2 0 2 4 6 8 10 12 14 16 10.0 8.0 (x103/mm3) Neutrophil 6.0 0.50mg Counts LLN 4.0 ULN 2.0 0.0 -4 -2 0 2 4 6 8 10 12 14 16 3.5 3.0 Lymphocyte (x103/mm3) 2.5 Counts 2.0 0.50mg LLN 1.5 ULN 1.0
Slide 17: Subject E, Female (1.0mg) - Efficacy
Subject E, Female (1.0mg) - Efficacy Visit Baseline Week 1 Week 2 Week 4 Week 6 Week 8 Week 12 Week 16 Dosing Duration 18FEB 24APR (65 days) PASI Score 12.1 9.9 5.1 3.4 2 1.6 3 3 PSSI Score 21 18 6 0 0 0 0 0 sPGA Score 3 3 1 1 1 1 1 1 BSA 10 10 6 4 3 3 4 4 Itch NRS 3 0 2 0 1 2 3 6 Joint Pain NRS N/A
Slide 18: Subject E, Female (1.0mg) - Serum Biomarkers
Subject E, Female (1.0mg) - Serum IL19, IL17A, IL17F & IL22 Biomarkers IL19, pg/ml IL17A, pg/ml 40 0.5 35 0.4 30 IL17A, pg/ml IL19, pg/ml 25 0.3 20 15 -71% 0.2 -83% 10 0.1 5 0 0 0 2 4 6 8 10 12 14 16 0 2 4 6 8 10 12 14 16 Study Week Study Week IL17F, pg/ml IL22, pg/ml 3.5 5 3 4 2.5 -66% IL22, pg/ml
Slide 19: Subject E, Female (1.0mg) - Safety & Key Labs
Subject E, Female (1.0mg) - Safety & Key Labs 500 400 (x103/mm3) Nadir at Platelet Counts 300 Week 4 1.00mg 200 LLN ULN 100 0 -4 -2 0 2 4 6 8 10 12 14 16 10.0 8.0 (x103/mm3) Neutrophil Counts 6.0 1.00mg LLN 4.0 ULN 2.0 0.0 -4 -2 0 2 4 6 8 10 12 14 16 3.5 3.0 Lymphocyte (x103/mm3) 2.5 Counts 2.0 1.00
Slide 20: Subject F, Male (1.0mg) - Efficacy
Subject F, Male (1.0mg) - Efficacy Visit Baseline Week 1 Week 2 Week 4 Week 6 Week 8 Week 12 Dosing Duration 18MAR 02APR (14 days) PASI Score 14.2 13.8 12.2 13.8 15.1 15.1 - PSSI Score 54 54 30 30 30 35 - sPGA Score 3 3 3 3 3 3 - BSA 18 18 16 18 18 18 - Itch NRS 7 1 1 5 1 1 - Joint Pain NRS N/A N/A
Slide 21: Subject F, Male (1.0mg) - Serum Biomarkers
Subject F, Male (1.0mg) - Serum IL19, IL17A, IL17F & IL22 Biomarkers IL19, pg/ml IL17A, pg/ml 160 1.4 140 1.2 120 1 IL17A, pg/ml IL19, pg/ml 100 0.8 80 -65% 0.6 -55% 60 40 0.4 20 0.2 0 0 0 2 4 6 8 10 12 14 16 0 2 4 6 8 10 12 14 16 Study Week Study Week IL17F, pg/ml IL22, pg/ml 7 12 6 10 5 -42% IL17F
Slide 22: Subject F, Male (1.0mg) - Safety & Key Labs
Subject F, Male (1.0mg) - Safety & Key Labs 500 400 (x103/mm3) Platelet Counts 300 1.00mg 200 LLN 100 ULN 0 -4 -2 0 2 4 6 8 10 12 14 16 10.0 8.0 (x103/mm3) Neutrophil Counts 6.0 1.00mg LLN 4.0 ULN 2.0 0.0 -4 -2 0 2 4 6 8 10 12 14 16 3.5 3.0 Lymphocyte (x103/mm3) Counts 2.5 1.00mg 2.0 1.5 LLN 1.0 ULN
Slide 23: Subject G, Male (1.0mg) - Efficacy
Subject G, Male (1.0mg) - Efficacy Visit Baseline Week 1 Week 2 Week 4 Week 6 Week 8 Week 12 Dosing Duration 01APR 02APR (2 days) PASI Score 18 2.7 3.6 3 2.2 3.3 - PSSI Score 12 - - - - - - sPGA Score 4 1 1 1 1 1 - BSA 11.5 3.5 3.5 2 3 3 - Itch NRS 6 7 7 7 5 7 - Joint Pain NRS N/A N/A N/A N/A N/A N/
Slide 24: Subject G, Male (1.0mg) - Serum Biomarkers
Subject G, Male (1.0mg) - Serum IL19, IL17A, IL17F & IL22 Biomarkers IL19, pg/ml IL17A, pg/ml 20 2 15 1.5 No No IL17A, pg/ml IL19, pg/ml 10 change 1 change 5 0.5 0 0 0 2 4 6 8 10 12 14 16 0 2 4 6 8 10 12 14 16 Study Week Study Week IL17F, pg/ml IL22, pg/ml 3.5 5 3 4 2.5 IL17F, pg/ml IL22, pg/ml 2 No
Slide 25: Subject G, Male (1.0mg) - Safety & Key Labs
Subject G, Male (1.0mg) - Safety & Key Labs 500 400 (x103/mm3) Platelet Counts 300 1.00mg 200 LLN 100 ULN 0 -4 -2 0 2 4 6 8 10 12 14 16 10.0 8.0 (x103/mm3) Neutrophil Counts 6.0 1.00mg 4.0 LLN ULN 2.0 0.0 -4 -2 0 2 4 6 8 10 12 14 16 3.5 3.0 Lymphocyte (x103/mm3) Counts 2.5 2.0 1.00mg 1.5 LLN 1.0 ULN
Slide 26: Visual Improvements in Psoriasis in 6 weeks
Visual Improvements in Psoriasis in 6 weeks Confidential – For Internal Use Only. Subject B (0.25mg) Last Dose Administered Day 64 Right Elbow Day 1 Week 6 Week 12 (PASI 13.9) (PASI 6.9) (PASI 5.4) 26
Slide 27: Visual Improvements in Psoriasis in 6 weeks
Visual Improvements in Psoriasis in 6 weeks Confidential – For Internal Use Only. Subject B (0.25mg) Last Dose Administered Day 64 Left Elbow Day 1 Week 6 Week 12 (PASI 13.9) (PASI 6.9) (PASI 5.4)
Slide 28: Visual Improvements in Psoriasis in 6 weeks
Visual Improvements in Psoriasis in 6 weeks Confidential – For Internal Use Only. Subject B (0.25mg) Back Scalp Day 1 (PSSI 14) Week 6 Week 12 (PSSI 4) (PSSI 1) 28
Slide 29: Visual Improvements in Psoriasis in 6 weeks
Visual Improvements in Psoriasis in 6 weeks Confidential – For Internal Use Only. Subject E (1mg) Last Dose Administered Day 65 Right Elbow Day 1 Week 6 Week 12 (PASI 12.1) (PASI 2.0) (PASI 3.0) 29
Slide 30: Visual Improvements in Psoriasis in 6 weeks
Visual Improvements in Psoriasis in 6 weeks Confidential – For Internal Use Only. Subject E (1mg) Last Dose Administered Day 65 Left Elbow Day 1 Week 6 Week 12 (PASI 12.1) (PASI 2.0) (PASI 3.0) 30
Slide 31: Data Summary
Data Summary Confidential – For Internal Use Only. Safety and Tolerability Exploratory Efficacy • No TESAEs or discontinuation due to a clinical TEAE • All subjects receiving VYN202 had an improvement in signs and symptoms of disease, including scalp psoriasis: • No treatment interruptions due to a
Slide 32: Appendix
Appendix %VYNE’
Slide 33: Individual PASI Score Changes
Individual PASI Score Changes Subject 0% A (Placebo) B (0.25mg) PASI % Change from Baseline C (0.5mg) -20% D (0.5mg) E (1mg) Individual Patient F (1mg) G (1mg) -40% PASI50 -60% PASI75 -80% PASI90 -100% 0 1 2 4 6 8 10 12 14 16 Rapid onset of action within 4 weeks Weeks for all subjects on active drug
Slide 34: Serum Inflammatory Biomarkers: Maximum % Change from Baseline
Serum Inflammatory Biomarkers IL19 IL17A IL17F IL22 20 20 20 20 10 10 10 10 Maximum % Change from Baseline 0 N/A N/C 0 N/A N/C 0 N/C N/A N/C 0 N/A N/C -10 -10 -10 -10 -20 -20 -20 -20 -30 -30 -30 -30 -40 -40 -40 -40 -50 -50 -50 -50 -60 -60 -60 -60 -70 -70 -70 -70 -80 -80 -80 -80 -90 -90 -90 -90 A B C
Slide 35: Selected Laboratory Data
Preliminary Data available as of 6/20 Selected Laboratory Data • All data within Upper and Lower Limits of Normal (ULN/LLN) Platelet Count (103/mm3) • No grades of thrombocytopenia and trends in platelet counts reach a nadir between 4 and 6 weeks and increase during treatment • No grades of Neutrope
VYNE Therapeutics — Technical Presentation (July 2025) on 6ix